NCT05065801View on ClinicalTrials.gov

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

March 30, 2026

Study Completion Date

October 30, 2027

Conditions
Metastatic Pancreatic Cancer
Interventions
COMBINATION_PRODUCT

GEMBRAX/FOLFIRINOX Arm A

Patients in the experimental arm received sequential treatment: A maximum of 6 cycles (12 months) of chemotherapy; One cycle = 3 administrations of GEMBRAX followed by 2 administrations of FOLFIRINOX

COMBINATION_PRODUCT

FOLFIRINOX Arm B

Patients in this arm received : A maximum of 3 cycles (6 months) of chemotherapy. One cycle = 4 administrations of FOLFIRINOX

Trial Locations (8)

21079

RECRUITING

Centre Georges-François Leclerc, Dijon

34295

RECRUITING

CHU St Eloi, Montpellier

34298

RECRUITING

Institut régional du Cancer de Montpellier, Montpellier

38000

NOT_YET_RECRUITING

CHU Grenoble, Grenoble

42000

ACTIVE_NOT_RECRUITING

CHU St Etienne, Saint-Etienne

51100

RECRUITING

Institut GODINOT, Reims

66000

NOT_YET_RECRUITING

Centre Catalan d'Oncologie, Perpignan

66046

RECRUITING

CH de Perpignan, Perpignan

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER